Table 1.

Relationship of lncMa-301 expression and overall survival with demographic and clinical data in HCC patients

Variable	lncMa-301 expression				Overall survival analysis
	Low (n = 108)	High (n = 108)	Odds ratio (95%CI)	P	No. of patients	Hazard ratio (95%CI)	P
Sex
Female	13	16	0.79 (0.36–1.73)	0.549	29	Ref.	0.184
Male	95	92	Ref.		187	2.00 (0.72–5.57)
Age, year
< 60	84	90	0.70 (0.36–1.38)	0.302	174	Ref.	0.144
≥ 60	24	18	Ref.		42	0.53 (0.23–1.24)
Size, cm
< 5	29	35	0.77 (0.43–1.38)	0.371	64	Ref.	0.016
≥ 5	79	73	Ref.		152	2.67 (1.20–5.95)
Number of tumors
< 3	97	99	0.80 (0.32–20.2)	0.639	196	Ref.	0.023
≥ 3	11	9	Ref.		20	2.42 (1.13–5.17)
Tumor capsule
Complete	59	65	0.80 (0.46–1.37)	0.409	124	Ref.	0.015
Incomplete/absent	49	43	Ref.		92	2.03 (1.15–3.58)
Lymph node metastasis
No	99	104	0.42 (0.13–1.42)	0.153	203	Ref.	0.006
Yes	9	4	Ref.		13	3.06 (1.37–6.81)
Macrovascular invasion
No	66	69	0.89 (0.51–1.54)	0.673	135	Ref.	< 0.001
Yes	42	39	Ref.		81	2.92 (1.65–5.16)
Microvascular invasion
No	42	45	0.89 (0.52–1.54)	0.677	87	Ref.	< 0.001
Yes	66	63	Ref.		129	4.04 (1.89–8.62)
AFP, ng/mL
< 400	53	55	0.93 (0.55–1.58)	0.785	108	Ref.	0.181
≥ 400	55	53	Ref.		108	1.47 (0.84–2.59)
BCLC stage
0/A	47	51	0.86 (0.50–1.47)	0.585	98	Ref.	0.001
B/C	61	57	Ref.		118	2.94 (1.53–5.65)
EST031.1 expression
Low	108	0		NA	108	Ref.	0.036
High	0	108			108	0.54 (0.30–0.96)

Bold values indicate P value less than 0.05

AFP alpha fetoprotein, BCLC Bacelona Clinic Liver Cancer, CI confidence interval, HCC hepatocellular carcinoma, Ref. reference